Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-22T08:04:23.882Z Has data issue: false hasContentIssue false
  • English
  • Français

Optimizing Treatment in Social Phobia: A Review of Treatment Resistance

Published online by Cambridge University Press:  07 November 2014

Michael Van Ameringen ,
Catherine Mancini ,
Beth Pipe  and
Mark Bennett
Get access Rights & Permissions [Opens in a new window]

Abstract

Over the last 25 years, there has been a rapid expansion of our knowledge base of social phobia (SP). Although there are a number of well-validated treatment modalities, including pharmacotherapy and cognitive-behavioral therapy, significant gaps remain in our ability to achieve full remission in most patients. Despite advances in the neurobiology of SP, the etiology has yet to be determined. Investigations examining potential predictors of response have provided little guidance in selecting an appropriate treatment modality. These gaps in our knowledge have pushed us to examine issues related to treatment resistance. This paper presents a review of the current literature and issues related to treatment-resistant SP, including a discussion of the functional impairment associated with SP, definitions of treatment response and remission, as well as outcome measures that have been used in clinical investigations of SP. In addition, criteria for a standard treatment trial, predictors of treatment response, a review of treatment resistance studies, and potential directions for future research are examined. The most promising strategies to attain remission, will likely involve augmenting selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors with agents such as anticonvulsants, benzodiazepines, and antipsychotics as well as combining pharmacotherapy with cognitive-behavioral therapy. Our current treatment target of simply attaining a response needs to be refocused, so that an asymptomatic state and high end state functioning become the final goal of treatment.

Type
Review Articles
Information
CNS Spectrums , Volume 9 , Issue 10 , October 2004 , pp. 753 - 762
Copyright
Copyright © Cambridge University Press 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar
2.Kessler, RC, McGonagle, KA, Zhao, S, et al.Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8–19.CrossRefGoogle ScholarPubMed
3.Mathew, SJ, Coplan, JD, Gorman, JM. Neurobiological mechanisms of social anxiety disorder. Am J Psychiatry. 2001;158:1558–1567.CrossRefGoogle ScholarPubMed
4.Gelernter, CS, Uhe, TW, Cimbolic, P, et al.Cognitive-behavioral and pharmacological treatment of social phobia. A controlled study. Arch Gen Psychiatry. 1991;48:938–945.CrossRefGoogle ScholarPubMed
5.Liebowitz, MR, Schneier, P, Campeas, R, et al.Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry. 1992;49:290–300.CrossRefGoogle ScholarPubMed
6.Heimberg, RG, Liebowitz, MR, Hope, DA, et al.Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12 week outcome. Arch Gen Psychiatry. 1998;55:1133–1141.CrossRefGoogle ScholarPubMed
7.Fahlen, T, Nilsson, HL, Borg, K, Humble, M, Pauli, U. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. Acta Psychiatr Scand. 1995;92:351–358.CrossRefGoogle ScholarPubMed
8.van Vliet, IM, den Boer, JA, Westenberg, HG. Psychopharmacological treatment of social phobia: clinical and biological effects of brofaromine, a selective MOA-A inhibitor. Eur Neuropsychopharmacol. 1992;2:21–29.CrossRefGoogle Scholar
9.Versani, M, Nardi, AE, Mundim, FD, et al.The long-term treatment of social phobia with moclobemide. Int Clin Psychopharmacol. 1996;11 (suppl 3):83–88.CrossRefGoogle Scholar
10.Davidson, JRT, Potts, NS, Richichi, E, et al.Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol. 1993;13:423–428.CrossRefGoogle ScholarPubMed
11.Verisani, M, Nardi, AE, Figueria, I, et al.Double-blind placebo-controlled study of bromazepam in social phobia. Serie psicofarmacologia-59. J Bass Psiquitr. 1997;46:167–171.Google Scholar
12.Van Vliet, IM, den Boer, JA, Westenberg, HG. Psychopharmacological treatment of social phobia; a double-blind placebo controlled study with fluvoxamine. Psychopharmacol. 1994;115:128–134.CrossRefGoogle ScholarPubMed
13.Stein, MB, Fyer, AJ, Davidson, JR, Pollack, MH, Wiita, B. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry. 1995;156:756–760.CrossRefGoogle Scholar
14.Davidson, JRT, Hemby, LW, Barbato, L, et al. Fluvoxamine controlled release for the treatment of generalized social anxiety disorder. Poster presented at: annual meeting of the American College of Neuropsychopharmacology. December 10-14, 2000; San Juan, Puerto Rico.Google Scholar
15.Katzelnick, DJ, Kobak, KA, Greist, JH, Jefferson, JW, Mantle, JM, Serlin, RC. Sertraline for social phobia: a double-blind, placebo controlled crossover study. Am J Psychiatry. 1995;152:1368–1371.Google ScholarPubMed
16.Van Ameringen, MA, Lane, KM, Walker, JR, et al.Sertraline treatment for generalized social phobia: a 20-week, double-blind, placebo controlled study. Am J Psychiatry. 2001;158:275–281.CrossRefGoogle ScholarPubMed
17.Blomoff, S, Haug, TT, Hellstrom, K, et al.Randomised controlled general practice trial of sertraline, exposure therapy, and combined treatment in generalized social phobia. Br J Psychiatry. 2001;179:23–30.CrossRefGoogle Scholar
18.Stein, MB, Leibowitz, MR, Lydiard, RB, et al.Paroxetine treatment for generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA. 1998;280:708–713.CrossRefGoogle ScholarPubMed
19.Baldwin, D, Bobes, J, Stein, DJ, Scharwachter, I, Faure, M. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry. 1999;175:120–126.CrossRefGoogle ScholarPubMed
20.Davidson, JR. Pharmacotherapy of social anxiety disorder. J Clin Psychiatry. 1998;59:47–51.Google ScholarPubMed
21.Allgulander, C. Paroxetine in social anxiety disorder: a randomized placebocontrolled study. Acta Psychiatr Scand. 1999;100:193–198.CrossRefGoogle Scholar
22.Stein, MB, Pollack, MH, Mangano, R. Long-term treatment of generalized SAD with venlafaxine extended release. Abstract presented at: the annual meeting of the American Psychiatric Association. May 17-22, 2003; San Francisco, Calif.Google Scholar
23.Pande, AC, Davidson, JR, Jefferson, JW, et al.Treatment of gabapentin: a placebo-controlled study. J Clin Psychopharmacol. 1999;19:341–348.CrossRefGoogle ScholarPubMed
24.Feltner, DE, Pollack, MH, Davidson, JR, et al. A placebo-controlled study of pregabalin in the treatment of social phobia. Poster presented at: annual meeting of the Anxiety Disorders Association of America. March 23-26, 2000; Washington, DC.Google Scholar
25.Blanco, C, Schneier, FR, Schmidt, A, et al.Pharmacological treatment of social anxiety disorder: a meta-analysis. Depress Anxiety. 2003;18:29–40.CrossRefGoogle ScholarPubMed
26.Schneier, FR, Heckelman, LR, Garfinkel, R, et al.Functional impairment in social phobia. J Clin Psychiatry. 1994;55:322–331.Google ScholarPubMed
27.Van Ameringen, M, Mancini, C, Farvolden, P. The impact of anxiety disorders on educational achievement. J Anxiety Disord. 2003;17:561–571.CrossRefGoogle ScholarPubMed
28.Katzelnick, DJ, Kobak, KA, DeLeire, T. Impact of generalized social anxiety disorder in managed care. Am J Psychiatry. 2001;158:1999–2007.CrossRefGoogle ScholarPubMed
29.Patel, A, Knapp, M, Henderson, J, Baldwin, D. The economic consequences of social phobia. J Affect Disord. 2002;68:221–233.CrossRefGoogle ScholarPubMed
30.Davidson, JR, Hughes, DC, George, LK, Blazer, DG. The boundary of social phobia. Exploring the threshold. Arch Gen Psychiatry. 1994;51:975–983.CrossRefGoogle ScholarPubMed
31.Wittchen, HU, Fuetsch, M, Sonntag, H, et al.Disability and quality of life in pure and comorbid social phobia: findings from a controlled study. Eur Psychiatry. 2000;15:46–58.CrossRefGoogle ScholarPubMed
32.Fava, M. Diagnosis and definition of treatment-resistant depression. Biol Pschiatry. 2003;53:649–659.CrossRefGoogle ScholarPubMed
33.Ballenger, JC, Davidson, JR, Lecrubier, Y, et al.Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 1998;59(suppl 17):54–60.Google Scholar
34.Fava, GA, Grandi, S, Rafanelli, C, et al.Long-term outcome of social phobia treated by exposure. Psychol Med. 2001;31:899–905.CrossRefGoogle ScholarPubMed
35.Stein, DJ, Hunter, B, Rolfe, T, et al. Paroxetine in social anxiety disorder: a remission analysis. Poster presented at: annual meeting of the European College of Neuropsychopharmacology Congress. October 5-9, 2002; Barcelona, Spain.Google Scholar
36.Mennin, DS, Fresco, DM, Heimberg, RG, et al.Screening for social anxiety disorder in the clinical setting: using the Liebowitz Social Anxiety Scale. J Anxiety Disord. 2002;16:661–673.CrossRefGoogle ScholarPubMed
37.Stein, DJ, Kasper, S, Matsunaga, H, et al.Pharmacotherapy of social anxiety disorder: an algorithm for primary care—2001. Prim Care Psychiatry. 2001;7:107–110.CrossRefGoogle Scholar
38.Bandelow, B, Zohar, J, Hollander, E, et al.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry. 2002;3:171–199.CrossRefGoogle ScholarPubMed
39.Versiani, M, Mundim, FD, Nardi, AE, et al.Tranylcypromine in social phobia. J Clin Psychopharmacol. 1988;8:279–283.CrossRefGoogle ScholarPubMed
40.Versiani, M, Amrein, R, Montgomery, SA. Social phobia: long-term treatment outcome and prediction of response—a moclobemide study. Int Clin Psycopharmacol. 1997;12:239–254.CrossRefGoogle ScholarPubMed
41.Sutherland, SM, Tupler, LA, Colket, JT, et al.A 2-year follow-up of social phobia: status after a brief medication trial. J Nerv Ment Dis. 1996;184:731–738.CrossRefGoogle ScholarPubMed
42.Otto, MW, Pollack, MH, Gould, RA, et al.A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia. J Anxiety Disord. 2000;14:345–358.CrossRefGoogle ScholarPubMed
43.Slaap, BR, van Vliet, IM, Westenberg, HGM, et al.Responders and non-responders to drug treatment in social phobia: differences at baseline and prediction of response. J Affect Disord. 1996;39:13–19.CrossRefGoogle ScholarPubMed
44.Montgomery, SA. Implications of the severity of social phobia. J Affect Disord. 1998;50:S17–S22.CrossRefGoogle ScholarPubMed
45.Stein, DJ, Stein, MB, Pitts, CD, et al.Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. J Clin Psychiatry. 2002;63:152–155.CrossRefGoogle ScholarPubMed
46.Van Ameringen, M, Oakman, J, Mancini, C, et al.Predictors of response in generalized social phobia: effect of age of onset. J Clin Psychopharmacol. 2004;24:42–48.CrossRefGoogle ScholarPubMed
47.Massion, AO, Dyck, IR, Shea, MT, et al.Personality disorders and time to remission in generalized anxiety disorder, social phobia, and panic disorder. Arch Gen Psychiatry. 2002;59:434–440.CrossRefGoogle ScholarPubMed
48.Chambless, DL, Tran, GQ. Predictors of response to cognitive-behavioral group therapy for social phobia. J Anxiety Disord. 1997;11:221–240.CrossRefGoogle ScholarPubMed
49.Oosterbaan, DB, van Balkom, AJ, Spinhoven, P, de Meij, TG, van Dyck, R. The influence on treatment gain of comorbid avoidant personality disorder in patients with social phobia. J Nerv Ment Disord. 2002;190:41–43.CrossRefGoogle ScholarPubMed
50.Turner, SM, Beidel, DC, Wolff, PL, Spaulding, S, Jacob, RG. Clinical features affecting treatment outcome in social phobia. Behav Res Ther. 1996;34:795–804.CrossRefGoogle ScholarPubMed
51.Wlazlo, Z, Schroeder-Hartwig, K, Hand, I, Kaiser, G, Munchau, N. Exposure in vivo vs social skills training for social phobia: long-term outcome and differential effects. Behav Res Ther. 1990;28:181–193.CrossRefGoogle ScholarPubMed
52.Cameron, OG, Thyer, BA, Feckner, S, Nesse, R, Curtis, GC. Behavior therapy of phobias: predictors of outcome. Psychiatry Res. 1986;19:245–246.CrossRefGoogle ScholarPubMed
53.Scholing, A, Emmelkamp, PMG. Prediction of treatment outcome in social phobia: a cross-validation. Behav Res Ther. 1999;37:659–670.CrossRefGoogle ScholarPubMed
54.Altamura, AC, Pioli, R, Vitto, M, Mannu, P. Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders. Int Clin Psychopharmacol. 1999;14:239–245.CrossRefGoogle ScholarPubMed
55.Aarre, TF. Phenelzine efficacy in refractory social anxiety disorder: a case series. Nord J Psychiatry. 2003;57:313–315.CrossRefGoogle ScholarPubMed
56.Van Ameringen, M, Mancini, C, Wilson, C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord. 1996;39:115–121.CrossRefGoogle ScholarPubMed
57.Kinrys, G, Soldani, F, Hsu, D, et al. Adjunctive tiagabine for treatment refractory social anxiety disorder. Poster presented at: annual meeting of the American Psychiatric Association. May 1-6, 2004; New York, NY.Google Scholar
58.Stein, MB, Sareen, J, Hami, S, Chao, J. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry. 2001;158:1725–1727.CrossRefGoogle ScholarPubMed
59.Hollander, E, Beinstock, CA, Pallanti, S, et al.Refractory obsessive-compulsive disorder: state-of-the-art treatment. J Clin Psychiatry. 2002;63(suppl 6):20–29.Google ScholarPubMed
60.McIntyre, R, Katzman, M. The role of atypical antipsychotics in bipolar depression and anxiety disorders. Bipolar Disord. 2003;5(suppl 2):20–35.CrossRefGoogle ScholarPubMed
61.Kennedy, SH, Lam, RW. Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics. Bipolar Disord. 2003;5(suppl 2):36–47.CrossRefGoogle ScholarPubMed
62.Ruck, C, Andreewitch, S, Flyckt, K, et al.Capsulotomy for refractory anxiety disorders: long-term follow-up of 26 patients. Am J Psychiatry. 2003;160:513–521.CrossRefGoogle ScholarPubMed
63.Telaranta, T. Treatment of social phobia by endoscopic thoracic sympathicotomy. Eur J Surg. 1998;580(suppl):27–32.Google Scholar
64.Pohjavaara, P, Telaranta, T, Vaisanen, E. The role of the sympathetic nervous system in anxiety: Is it possible to relieve anxiety with endoscopic sympathetic block? Nord J Psychiatry. 2003;57:55–60.CrossRefGoogle ScholarPubMed
65.Heimberg, RG. Cognitive-behavioral therapy for social anxiety disorder: current status and future directions. Biol Psychiatry. 2002;51:101–108.CrossRefGoogle ScholarPubMed
66.Blomhoff, S, Haug, TT, Hellstrom, K, et al.Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry. 2001;179:23–30.CrossRefGoogle ScholarPubMed
67.Haug, TT, Blomhoff, S, Hellstrom, K, et al.Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomized controlled trial. Br J Psychiatry. 2003:182:312–318.CrossRefGoogle Scholar
68.Clark, DM, Ehlers, A, McManus, F, et al.Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo controlled trial. J Consult Clin Psycol. 2003;71:1058–1067.CrossRefGoogle ScholarPubMed
69.Foa, EM, Davidson, JRT, Huppert, JD, et al. Comprehensive CBT, fluoxetine, and their combination: a randomized placebo-controlled trial. Paper presented at: annual meeting of the Association for the Advancement of Behavior Therapy. November 20-23, 2003; Boston, Mass.Google Scholar
70.Kobak, KA, Greist, JH, Jefferson, JW, et al.Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol. 2002;22:257–262.CrossRefGoogle ScholarPubMed
71.Heimberg, RG. Cognitive behavioral and psychotherapeutic strategies for social anxiety disorder. Paper presented at: annual meeting of the Anxiety Disorders Association of America. March 27-30, 2003; Toronto, Canada.Google Scholar
72.Pope, HG Jr, McElroy, SL, Keck, PE Jr, Hudson, JI. Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry. 1991;48:62–68.CrossRefGoogle Scholar
73.Maltese, TM. Adjunctive lamotrigine treatment for major depression. Am J Psychiatry. 1999;156:1833CrossRefGoogle ScholarPubMed
74.Steinacher, L, Vandel, P, Zullino, DF, et al.Carbamazepine augmentation in depressive patients non-responding to citralopram: a pharmacokinetic and clinical pilot study. Eur Neuropsychopharmacol. 2002;12:255–260CrossRefGoogle Scholar
75.Papp, LA, Ninan, PT. Tiagabine for the treatment of social anxiety disorder. Paper presented at: annual meeting of the American Psychiatric Association. May 1-6, 2004. New York, NY.Google Scholar
76.Simon, N, Worthington, JJ, Doyle, AC, et al.Levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry. In press.Google Scholar
77.Van Ameringen, M, Mancini, C, Pipe, B, Oakman, J, Bennett, M. An opentrial of topiramate in generalized social phobia. J Clin Psychiatryjt. In press.Google Scholar
78.Nardi, AE, Mendolwicz, M, Versiani, FM. Valproic acid in social phobia- An open trial [abstract]. Biol Psychiatry. 1997;42:118S.CrossRefGoogle Scholar
79.Kinrys, G, Pollack, MH, Simon, NM, Worthington, JJ, Nardi, AE, Versiani, M. Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol. 2003;18:169–172.Google ScholarPubMed
80.Seedat, S, Stein, MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry. 2004; 65:244–248.Google ScholarPubMed
81.McDougle, CJ. Barr, LC, Goodman, WK, et al.Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry. 1995;152:1812–1814.Google ScholarPubMed
82.Butterfield, MI, Becker, ME, Connor, KM, Sutherland, S, Churchill, LE, Davidson, JR. Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Int Clin Psychopharmacol. 2001;16:197–203.CrossRefGoogle ScholarPubMed
83.Denys, D, Van Megen, H, Westenberg, H. A double-blind, placebo-controlled study of quetiapine addition in treatment refractory patients with OCD. Poster presented at: annual meeting of the American Psychiatric Association. May 17-22, 2003; San Francisco, Calif.Google Scholar
84.Stein, MB, Kline, NA, Matloff, JL. Adjunctive Olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry. 2002;159:1777–1779.CrossRefGoogle ScholarPubMed
85.Khaldi, S, Kornreich, C, Dan, B, Pelc, I. Usefulness of olanzapine in refractory panic attacks. J Clin Psychopharmacol. 2003;23:100–101.CrossRefGoogle ScholarPubMed
86.Barnett, SD, Kramer, ML, Casat, CD, et al.Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol. 2002;16:365–368.CrossRefGoogle ScholarPubMed
87.Hoge, EA, Reese, HE, Doyle, AC, et al. Risperidone for the treatment of refractory panic, social anxiety, and generalized anxiety disorders. Poster presented at: annual meeting of the Anxiety Disorders Association of America. March 11-14, 2004; Miami, FL.Google Scholar
88.Van Ameringen, M, Mancini, C. The promise of neurobiology in social phobia. In: Bandelow, B, Stein, DJ, eds. Social Anxiety Disorder. New York, NY: Marcel Dekker, Inc., 2004:181–196.Google Scholar
89.Simpson, HB, Schneier, FR, Marshall, RD, et al.Low dose selegiline (L-Deprenyl) in social phobia. Depress Anxiety. 1998;7:126–1293.0.CO;2-9>CrossRefGoogle ScholarPubMed
90.Villarreal, G, Johnson, MR, Rubey, R, et al.Treatment of social phobia with the dopamine agonist pergolide. Depress Anxiety. 2000;11:45–473.0.CO;2-8>CrossRefGoogle ScholarPubMed
91.Kennedy, SH, Lam, RW, Cohen, N, et al.Clinical guidelines for the treatment of depressive disorders IV. Medication and other biological treatments. Can J Psychiatry. 2001;46(suppl 1):38S–58S.Google ScholarPubMed